Multicompartment Lipid Nanocarriers for Targeting of Cells Expressing Brain Receptors - Self-Assembled Supramolecular Architectures: Lyotropic Liquid Crystals - page 318

TABLE 11.1 Summary of Diseases Related to BDNF Defi ciency in
View of Disorders Involving TrkB Receptor Signaling, and
Expected Roles of Therapeutic Molecules

Potential Roles for Therapeutic Molecular
Ligands upon Binding to TrkB Brain
Receptors

Pathological States Suggested
to Involve BDNF Mechanisms

Alzheimer ' s disease Agonist to compensate for BDNF defi ciency,

prevent neural degeneration, improve
synaptic transmission, promote plasticity,
promote neurogenesis

Huntington ' s disease Agonist to compensate for BDNF defi ciency

and to promote striatal neuron function

Parkinson ' s disease Agonist to upregulate D 3 receptor

expression and to protect dopaminergic
neurons

Rett syndrome Agonist to compensate for BDNF defi ciency

Motor neuron disease Agonist to inhibit motor neuron death

Depression Agonist to promote neurogenesis or

upregulate neurotransmitter function

Ischemic stroke Agonist to prevent neuronal death and/or to

upregulate neuronal function and promote
postinjury plasticity

HIV dementia Agonist to protect neurons from HIV - 1/

gp120 - induced death

Multiple sclerosis Agonist to mimic immunomediated BDNF

protective mechanisms in MS lesions

Spinal cord injury Agonist to promote axonal regeneration,

plasticity, and activation of TrkB without
p75 NTR liganding to overcome myelin
inhibition

Nerve injury Agonist to prevent postaxotomy neuron loss

and/or promote regeneration

Hearing loss Agonist to protect auditory neurons

Obesity, diabetes, and metabolic
syndrome

Agonist to limit food intake and correct
metabolic syndrome

Peripheral tissue ischemia Agonist to promote angiogenesis

Epilepsy Antagonist or partial agonist to inhibit

hyperexcitable circuits in injured brain

Pain Antagonist, partial agonist, or agonist to

suppress pain transmission

Cancer Agonist or partial agonist to inhibit TrkB -

dependent tumor therapeutic resistance
mechanisms

Source : Adapted from Longo (2010) .